<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighteen patients with Stage 4 B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1 </plain></SENT>
<SENT sid="1" pm="."><plain>Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicity was very modest except in one patient who developed <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody </plain></SENT>
</text></document>